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ABSTRACT Melanoma is one of the most aggressive tumors. It develops from pigment-forming cells (melanocytes) 
and results in a high number of lethal outcomes. The use of genetic constructs with the ability to specifically kill 
melanoma cells, but not normal cells, might increase the lifespan of patients, as well as improve their quality of 
life. One of the methods to achieve a selective impact for therapeutic genes on cancer cells is to utilize a tran-
scriptional control mechanism using promoters that are specifically activated only in cancerous cells. In this re-
view, promoters of the genes that are preferentially expressed in melanoma cells are described. These promoters, 
and other highly melanoma-specific regulatory elements, reduce the unspecific expression of therapeutic genes 
in normal tissues. Moreover, cancer-specific promoters and their elements are advantageous for the development 
of universal anticancer drugs. Examples of the use of double promoters that have a high potential as instruments 
in cancer gene therapy are also given in this review.
KEYWORDS melanoma; gene therapy; tissue-specific promoters; specific expression of a transgene
ABBREVIATIONS Ad – adenovirus; CRAds – conditionally replicative adenoviruses; DT-A – diphtheria toxin A 
chain; HSVtk – herpes simplex virus thymidine kinase; SCLC – small cell lung cancer; MC1R – melanocortin 1 
receptor; MIA – melanoma inhibitory activity, MITF – microphthalmia-associated transcription factor; TERT – 
human telomerase reverse transcriptase; TSP – tumor specific promoter; TSS – transcription start site
INTRODUCTION
A steady increase in deaths caused by malignant skin 
melanoma has recently been in evidence around the 
world, including in Russia. Malignant melanoma be-
longs to the most aggressive variety of tumors; the 
five-year survival rate of patients is less than 50%. Mel-
anoma especially stands out by its early metastazing; 
therefore, chemotherapy and radiation therapy are not 
very effective against the disease [1–3].
In the longer term, an important role could be played 
by gene therapy methods based on the introduction of 
a therapeutic gene (transgene) into melanoma cells in 
patients. Therapeutic contructs may contain genes that 
compensate for the reduction in the expression of sup-
pressor genes, which results in tumor development. Or 
conversely, they may contain genes whose products 
neutralize the increased expression of an undesirable 
gene (oncogene) [4–7]. The approach in which the so-
called suicide genes are used is considered to be one of 
the most universal strategies among genetic strategies 
for killing cancer cells [8–10]. In this case, a gene is in-
troduced into a tumor cell; which encodes an enzyme 
that is not typical for the normal cell and is capable of 
converting the compound that has no toxicity towards 
healthy cells (prodrug) into a toxin that results in the 
killing of tumor cells containing a suicide gene. Thus, 
the selective killing of cancer cells in which the suicide 
gene acts is provided [11–13]. The gene encoding the 
herpes simplex virus thymidine kinase (HSVtk) and the 
gene encoding yeast cytosine desaminase (FCY1) are 
the most widely known and the most frequently used 
suicide genes. As opposed to cellular thymidine kinase, 
HSVtk has the ability to phosphorylate the antiherpes 
drugs acyclovir and ganciclovir. The cells transformed 
by the HSVtk gene die in the presence of these agents, 
since cellular kinases convert the phosphorylated acy-
clovir and ganciclovir into triphosphates, which are 
inserted into the newly synthesized DNA upon cytoki-
nesis and terminate its subsequent synthesis. It is the 
dividing cells that die, rather than the resting cells, in 
which DNA is not synthesized and ganciclovir or acy-
clovir is not inserted [14]. The gene  HSVtk has been 
successfully used for the experimental therapy of nu-
merous types of tumors in animals. A number of sys-
tems comprising this gene have been undergoing clini-
cal trials [13, 15, 16]. The use of the FCY1 gene is based 
on the absence of its product, cytosine desaminase, in 
mammal cells and on its ability to convert 5-fluorocy-
tosine, which is not toxic to humans, into a known cy-
tostatic, 5-fluorouracil [17, 18]. After the incorporation 
of cytosine desaminase into tumor cells and its specific 
expression in these cells, the introduction of fluorocyto-
Copyright ©2011 Park­media, Ltd. This is an open access article distributed under the Creative
Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited.14 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
REVIEWS
sine into a patient’s organism results in its intracellular 
conversion into fluorouracil, which reduces the toxic 
effect that fluorouracil has on normal cells.
The specificity of the vector to tissue of this type can 
be specified either by delivering it exactly into the tis-
sue or by creating conditions for the specific expression 
of the transgene in the specified tissue. Due to its sim-
plicity, the latter method has been used more frequent-
ly. With this aim, promoters and enhancers that act 
specifically in the tumors of the given tissue are used in 
the construction of vectors [19, 20]. In the case of malig-
nant melanoma, promoters and enhancers of the genes 
that are involved in melanin biosynthesis are used. The 
fact that transgene expression is ensured only in tu-
mor cells, and not in normal cells, is an advantage of 
the promoters and other regulatory elements that are 
strictly specific to tumors of this type. However, their 
non-universality and the inevitable increase in the cost 
of drugs based on the promoters connected with this 
fact is a significant disadvantage of such approaches. 
A variant which offers a potential compromise consists 
in the use of more universal tumor-specific promoters 
capable of acting in a wide range of tumors, but not in 
normal cells. Although this approach slightly increases 
the risk of affecting normal tissues, it is considered to 
be more economically viable, since the same constructs 
can be used for the therapy of a wide range of tumors. 
An additional factor that supports promoters having a 
broader action spectrum is connected with the poorly 
studied specificity of gene expression in metastases 
of the given tumor. There is no strict guarantee that a 
narrow-specific promoter that acts well in a primary 
tumor will retain this ability in all its metastases. The 
use of universal promoters reduces the probability of 
promoter inactivation in metastases.
This review describes the structure and properties of 
promoters that are specific to melanoma cells and those 
that are active for a wide range of tumors but are still 
used in the gene therapy of melanoma.
PROMOTERS THAT ARE SPECIFICALLY 
ACTIVE IN MELANOCYTES 
The most well-studied promoter modules that control 
the specific expression of the therapeutic gene in mel-
anoma cells, with recent widespread application, are 
promoters of the tyrosinase gene (TYR) or the gene en-
coding the melanoma inhibitory activity (MIA), some-
times combined with distal elements of other promot-
ers and/or the enhancers [21, 22].
Tyrosinase gene promoter
Tyrosinase (TYR) is one of the key enzymes required for 
the synthesis of pigment melanin, which is formed only 
in melanocytes and in retinal pigment epithelium. The 
TYR gene is expressed only in the specified cells and in 
many (but not in all) human melanomas and serves as 
a good marker of melanocyte differentiation [23]. It has 
been shown that the 5’-region with respect to the tran-
scription start site (TSS) determines the specificity of 
tyrosinase gene expression [24, 25]. It was demonstrated 
by the deletion analysis that the minimal promoter of 
the human tyrosinase gene is likely to be located in co-
ordinates -209/+51 with respect to TSS [26] (Fig. A). A 
115 bp fragment is enough for a tissue-specific activity 
of the human TYR promoter [24]. This promoter frag-
ment contains three positive regulatory elements: the 
conservative element that is typical for melanocyte-spe-
cific promoters – M-box (-104/-37 from the TSS), linked 
with nine nucleotides that are known as CR1; the Sp1-
site (-45/-37 from the TSS); and the evolutionarily con-
servative element CR2 consisting of the E-box motif and 
the octamer element (-14/+1 from the TSS) overlapping 
with it [24]. It is significant that the octamer element in 
the TYR promoter is degenerate in many mammals, 
including mice [27]. The E-box contains the CANNTG 
motif, which binds bHLH family transcription factors 
(basic-helix-loop-helix). This motif was detected in TYR 
gene promoters in various animal species. A similar motif 
can be found within the M-box and the enhancer region 
of the tyrosinase gene [27]. Melanocyte-specific expres-
sion of the tyrosinase gene is activated upon the binding 
of the product of the MITF gene to the promoter region, 
including the M-box and the E-box starting region [24].
Promoters of the human and mouse tyrosinase genes 
are characterized by a high degree of identity of the nu-
cleotide sequence [25]. However, a functional comparison 
of the promoters of these genes for a human and a mouse 
has demonstrated that the human TYR promoter has a 
lower efficacy and specificity of expression in melano-
cytes in comparison with the mouse Tyr promoter [25]. 
It has been assumed that an enhancer plays a significant 
role in the activity of the human TYR promoter. The hu-
man TYR enhancer, termed tyrosinase distal element 
(TDE), is located at positions -2014/-1810 and contains 
the E-box [25]. The binding of two MITF transcription 
factors to the E-boxes found within both the promoter 
and enhancer is significant for the specific activity of the 
human tyrosinase gene [21].
A 200 bp enhancer identical to the human TYR en-
hancer was also found in the 5’-region of the mouse ty-
rosinase gene; however, only the promoter is essential 
for manifesting the specific activity of the mouse gene 
[26, 28].
Promoter of the gene encoding melanoma inhibitory 
activity (MIA)
The gene encoding the melanoma inhibitory activ-
ity (MIA) is expressed predominately in melanoma or REVIEWS
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chondrosarcoma cells, in certain adenocarcinomas and 
chondrocytes; however, it is inactive in normal melano-
cytes [29–31]. The MIA protein, the secreted inhibitor 
of cell growth, prevents the attachment of melanoma 
cells to the extracellular matrix, thus promoting inva-
sion and metastazing [32–34]. As opposed to the TYR 
gene promoter, the activity of the human  MIA gene 
promoter correlates with melanoma progression [35]. 
It has been known that the 1.4 kb-long region flank-
ing the 5’-fragment of the MIA gene with respect to 
the transcription starting site provides the specificity 
of expression of this gene only in melanoma cells, not in 
melanocytes [36]. By means of deletion analysis it has 
been demonstrated that the minimal promoter of the 
human MIA gene consists of 212 bp (positions -211/+1) 
and of 230 bp (-229/+1), in the case of the mouse MIA 
gene, as is shown in Fig. B. The elements of the pro-
moters of this gene for humans and mice, which are re-
sponsible for the specificity of expression in melanoma 
cells, are located at positions -212/-170 and -230/-130, 
respectively [36, 37]. The structure and size of the hu-
man and mouse MIA promoters are conservative and 
contain identical elements, which can differ only in 
their position [38]. Thus, both MIA promoters contain 
no TATA-box and/or CAAT-sequence near the tran-
scription start site. Site Sp1 is conservative and is locat-
ed at position -108/-103 in the human MIA promoter, 
and at 106/-101, in the mouse promoter. MIA promot-
ers contain multiple E-boxes with bHLH-binding sites 
[36] (Fig. B). The binding site of the NF-κB transcrip-
tion factor is also highly conservative in human and 
mouse genes; in addition, it is located at different posi-
tions (-207/-198 and -819/-811, respectively) [36]. De-
letion or mutation of this site results in a considerable 
decrease in human MIA promoter activity in melanoma 
cell lines [36]. Human and mouse MIA promoters also 
comprise such widespread elements as the binding sites 
α-INF-2, C/EBP, GATA-1, GM-CSF, NF-IL6, NF-
κB, TCF-2, etc. It is of interest that the activity of the 
MIA promoter may be dependent on the NF-κB factor, 
which controls the expression of the genes encoding 
the immune response, apoptosis, and cell cycle [36]. At 
the time of writing, nothing was yet known about the 
enhancer elements of the MIA gene.
Promoter of the melacortin receptor gene
The melanocortin 1 receptor (receptor MC1R) is ex-
pressed predominately in melanocytes and melanomas 
[39, 40]. MC1R is a transmembrane G-protein-coupled 
receptor of the α-melanocyte-stimulating hormone 
(α-MSH). High expression of the MC1R gene is also typ-
ical of the cell lines originating from primary and meta-
static melanomas [41]. Minor amounts of these recep-
tors are found in other tissues and cells; e.g., in testicles, 
ovary, adrenal glands, keratinocytes, dendrite cells, 
and activated monocytes [41, 42]. The 3.2 kb-long frag-
ment located in the 5’-region with respect to the TSS 
of the MC1R gene contains several Sp1-binding mo-
tifs, consensus sequences of the AP-1 and AP-2 sites, 
and several E-boxes. The MC1R gene promoter con-
tains no TATA- or CAAT-sequences near the TSS [43, 
44]. Melanocyte-specific expression of MC1R, similar to 
that of the tyrosinase gene, is activated upon binding of 
the MITF transcription factor to the E-box [45–48]. It 
has been shown that 150 bp located above the ATG co-
don of the MC1R gene are sufficient in order to initiate 
the melanocyte-specific transcription [49]. This mini-
mal promoter can be considered as one of the possible 
candidates for the transcriptional control of transgene 
expression in melanoma cells.
The use of heterologous regulatory elements to en-
hance melanoma promoters
The use of cis-regulatory elements based on various 
combinations of the tyrosinase gene promoter and ad-
ditional heterologous enhancers, which control tran-
scription for specific transgene expression in melano-
ma, has been described in a number of studies [21, 22, 
26]. It is apparent that the TYR promoter ensures high 
activity and specificity of the human TYR gene only 
in the presence of the enhancer element [25]. The con-
struct consisting of the human TYR promoter (209 bp) 
and two or more sequentially attached human TYR en-
hancers (200 bp each) exhibit the highest specific effect 
upon transfection of melanoma cell lines [26]. The dimer 
of the mouse tyrosinase gene enhancer linked with the 
mouse gene promoter also enhances the activity and 
specificity of the mouse gene [26]. Similar constructs 
were used when constructing the conditionally repli-
cating adenoviruses (CRAds), where the promoter of 
the adenoviral Е1А gene was substituted for the pro-
moter hTyr2E/P that is specifically active in melano-
mas and consists of the dimer of the human tyrosinase 
gene enhancer and the core promoter of this human 
gene [50]. The resulting adenoviruses manifested a pro-
nounced oncolytic effect on melanoma cell lines. The 
cytotoxic effect of these constructs was also compara-
ble in terms of the level of CRAd action with the strong 
nonspecific cytomegalovirus (CMV) promoter. Mean-
while, a strong decrease in the cytotoxic effect of the 
adenovirus on normal fibroblasts and keratinocytes 
was observed [50]. Thus, the use of the specific promot-
er in the E1A region of the adenovirus genome made it 
possible to attain a selective effect on melanoma cells. 
The binding of several enhancers of the mouse tyrosi-
nase gene had an even stronger effect on the activi-
ty and specificity of the human TYR promoter. Thus, 
when constructing oncolytic adenoviral vectors, the 16 | ACTA NATURAE |  VOL. 3  № 2 (9)  2011
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TETP promoter construct was used. It contained the 
core human tyrosinase promoter (TP) and a tandem 
consisting of four mouse tyrosinase gene enhancers (ty-
rosinase enhancer – TE) [51]. The use of this promoter 
to control the expression of the luciferase reporter gene 
enhanced the activity of the latter in melanoma cells 
by several orders of magnitude in comparison with the 
activity in non-melanoma cells [51]. The replacement 
of mouse enhancers by human enhancer sequences in 
these constructs resulted in only a 2–3-fold increase in 
reporter gene activity [51]. The same promoter (TETP) 
was used to control the expression of suicide genes that 
were delivered to melanoma cells by bacteria Listeria 
monocytogenes [52]. It was demonstrated earlier that 
avirulent listeria strains can penetrate into solid tumor 
cells and provide replication of the delivered plasmids 
in them [53–55]. Upon bacterial delivery of plasmids, in 
which the TETP promoter controls the suicide gene of 
purine nucleoside phosphorylase (PNP) or the chimer-
ic gene of cytosine desaminase and phosphoryl trans-
ferase (FCU1) of yeasts, the transgene is specifically 
expressed in B16 melanoma cells, but not in kidney 
COS-1 fibroblasts. If a nonspecific CMV promoter is 
used, the suicide genes are expressed in both cell lines 
[52].
The Tyrex2 promoter that contains the human TYR 
core promoter and the tandem that consists of two 
mouse tyrosinase gene enhancers may serve as another 
example of using heterologous regulatory elements in 
order to enhance the TYR promoter [56]. When con-
structing the adenoviral vector, this promoter was used 
to control the activity of the PNP suicide gene, which 
can convert prodrug 6-methylpurine deoxyribonucle-
oside into a highly toxic purine-base 6-methylpurine 
[57]. After treating melanoma cells with adenovirus Ty-
rex2-PNP and introducing the prodrug, approximately 
90% of the cells died. In nonmelanoma cell lines, there 
was a cytotoxic effect  only when  the nonspecific con-
stitutive CMV promoter was used [56].
The reporter gene of chloramphenicol acetyltrans-
ferase (CAT) and therapeutic genes HSVtk and DT-A 
(diphtheria toxin A-chain) were used to compare the 
activity of the mouse Tyr gene promoters and human 
MIA gene promoters and their combinations with one 
or several enhancers of the mouse tyrosinase gene [22]. 
Promoters of genes encoding Tyr, MIA, and various 
combinations of them with one or several enhancers of 
the mouse tyrosinase gene provided a specific expression 
of both the CAT reporter gene and therapeutic genes 
HSVtk and DT-A in melanoma cell lines. It was demon-
strated that the binding of several enhancers of the ty-
rosinase gene to the MIA promoter considerably enhanc-























Schematic presentation of the 
tyrosinase and melanoma in-
hibitory activity (MIA) promot-
ers. 
A – scheme of tyrosinase 
promoter, B – scheme of MIA 
promoter. The rectangle with 
diagonal hatching indicates 
an enhancer, open rectangle 
indicates the binding site of 
the transcription factor NF-κB, 
dark-gray rectangle – the M-
box, light-gray rectangle – the 
E-box, black rectangle – the 
binding site of the Sp1 factor, 
a loci corresponding to the 
minimal promoter is given in 
parentheses. The arrow shows 
the transcription start site.REVIEWS
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es the specific activity of the MIA promoter in melanoma 
cell lines; the effect of mouse enhancers is stronger by 
an order of magnitude in comparison with that from 
human TYR enhancers, similar to the case of using the 
tyrosinase gene promoter. The strongest effect in both 
cases was observed when using  constructs containing 
three or four mouse enhancers simultaneously [22].
The recombinant adeno-associated vector, in which 
the suicide gene is placed under the  MIA promoter 
linked to the tandem consisting of four enhancer el-
ements of the mouse tyrosinase gene, was described 
in [58]. The constructs with a full-size MIA promoter 
(1386 bp) and the minimal MIA promoter (493 bp) that 
is sufficient for maintaining the specific transcrip-
tion in melanoma cells have been studied (Fig. B). It 
was shown that the constructs containing only  MIA 
promoters have a low transcriptional activity only in 
melanoma cell lines [58]. The transcriptional potential 
of a construct with tyrosinase gene enhancers and the 
minimal MIA promoter was somewhat lower than that 
of the construction with the full-size promoter. The in-
hibition effect of melanoma cell growth with the use of 
MIA promoters with four tyrosinase gene enhancers is 
only slightly lower to the effect of the construct with 
the CMV-promoter; however, the latter does not pro- -promoter; however, the latter does not pro- promoter; however, the latter does not pro-
vide the selectivity of transgene expression [58].
The given results demonstrate that the use of vari-
ous combinations of melanoma-specific promoters and 
enhancers provides a high level of transgene expres-
sion in melanoma cells and can resolve the specificity 
problem for the gene therapy of the specified disease 
[50, 52, 56]. The MIA gene promoter is of special inter-
est, since this gene, as opposed to the TYR gene, is ex-
pressed only in malignant melanoma cells but not in 
other cells of the melanocyte lineage. Thus, the regula-
tory elements of this gene may combine both tissue-
specific and tumor-specific properties. However, the 
MIA gene promoter has still not been adequately stud-
ied as a candidate for the gene therapy of melanoma; 
almost nothing is known about the potential of the 
MC1R gene promoter.
PROMOTERS SPECIFICALLY ACTIVE IN CELLS 
OF MELANOMA AND OTHER TUMORS
Another approach that makes it possible to specifically 
control transgene expression in melanoma cells is the 
use of promoters that are specific not only in melano-
ma, but in other tumor cells as well. The examples of 
such tumor-specific promoters (TSP) include promot-
ers of the genes TERT, Cox-2, CXCR4, and BIRC5, for 
which overexpression of the genes controlled by them 
in numerous tumor types and the absence or a minimal 
expression in the normal tissues is typical.
The TERT gene encodes the catalytic subunit of hu-
man telomerase. This gene is active during the embry-
onic development and in tumor cells (in approximately 
85% of all cases), whereas the expression of TERT is sup-
pressed in the overwhelming majority of normal cells 
in the organism [59]. The level of TERT expression is in-
creased for superficial spreading melanoma [60], which 
is believed to prevent the cells from entering apoptosis. 
Cyclooxygenase 2 (Cox-2) is the inducible isoform of 
Cox-1, which cannot be detected in most normal tissues, 
as opposed to Cox-1 [61]. Expression of the Cox-2 gene is 
closely associated with cancerogenesis and the progres-
sion of certain types of intestinal neoplasias and tumors 
of epithelial origin [62, 63]. The Cox-2 gene is expressed 
at a high level in melanoma cells and is not expressed in 
nevus and in the normal epithelium of the gene [64].
The expression of the α-chemokine CDF-1 recep-
tor – CXCR4 gene is typical for breast cancer cells and 
virtually cannot be detected in the normal breast epi-
thelium [65]. Overexpression of the CXCR3 and CXCR4 
receptors was demonstrated in melanoma cells as well. 
It is assumed that receptors play a significant role upon 
melanoma invasion by modulating cell mobility, prolif-
eration, and survival [66].
Survivin encoded by the BIRC5 gene belongs to the 
group of apoptosis-inhibitory proteins; it plays an im-
portant role in the growth and progression of tumors 
of various types [67]. BIRC5 is expressed in embryonic 
and fetal tissues [68], many types of neoplasias, includ-
ing melanoma [69–71], and cannot be detected in dif-
ferentiated adult tissues [72].
Tumor-specific promoters can be used within the 
conditionally replicating adenoviruses (CRAds) that 
were described above to achieve the oncolytic effect. 
Thus, the TERT promoter was used instead of the E1A 
gene promoter for transcriptional control of adenovirus 
replication. Moreover, this construct contained the apo-
ptin gene under the strong constitutive CMV promoter 
[73]. Apoptin is a viral protein which specifically in-
duces the apoptosis of cancer cells [74]. Thus, a system 
is constructed possessing “double” tumor-specificity, 
which is determined by the TERT promoter (activated 
in tumor cells) and apoptin (which has a selective ef-
fect on tumor cells). When cells were infected with Ad-
TERT-Apoptin viruses, the growth of melanoma cells 
(line A375 and B16) was suppressed, resulting in apop-
tosis, whereas the normal epidermal melanocytes were 
protected from this effect [73]. Moreover, the reduction 
of lung metastases upon intratumoral and systemic ad-
ministration of the Ad-TERT-Apoptin construct was 
demonstrated on a model of mouse metastatic mela-
noma. When using this system, a higher mouse survival 
rate was also observed [73].
The potential benefits of using other tumor-specific 
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termining the activity of the luciferase reporter gene, 
when it is transcriptionally controlled by promoters of 
the Cox-2, CXCR4, and BIRC5 genes. Recombinant ad-
enoviruses containing one of the TSP promoters and 
the luciferase gene controlled by them, instead of the 
Е1 region, were used as a vector [75]. The luciferase 
activity was measured in four melanoma cell lines 
(Mel-624, A375M, SK-MEL-28 и MeWo) and in nor-
mal epithelial melanocytes (HEM) [75]. The  CXCR4 
gene promoter had no required specificity; its activ-
ity in the normal melanocytes was even higher than in 
melanoma cells [75]. Earlier, the transcriptional activ-
ity of the Cox-2 promoter that was inactive in primary 
melanocytes had been revealed in melanoma cell lines 
[76]. However, the activity of the Cox-2 gene promoter 
varies considerably depending on the cell line type [75]. 
The highest specific activity was demonstrated by the 
survivin gene promoter. Moreover, its activity in the 
normal melanocytes was considerably lower than it was 
in melanoma cells [75]. It has been recently shown that 
upon using the survivin gene promoter to control the 
expression of the iodide simporter (NIS) gene, the cells 
of the melanoma line A375 acquire the ability to uptake 
radioactive iodine-131, which has a negative effect on 
their survival [77]. Meanwhile, normal fibroblasts of 
human tooth pulp transfected by the same construct 
neither absorb iodine nor die. Thus, the survivin pro-
moter was the optimal one for melanoma therapy 
among the tumor-specific promoters under compari-
son.
The activity of most tumor-specific promoters is 
lower than that of constitutive strong promoters, such 
as the SV40 and CMV promoters [75, 78, 79]. The activ-
ity of even relatively strong tumor-specific promoters 
varies considerably depending on the type of cancer 
cells. In different tumor cell lines, the activity of the 
survivin gene promoter varies from 0.3 to 16% of the 
activity of the CMV promoter [80–82], while the effi-
cacy of the performance of the TERT promoter may 
differ by up to 20 fold [83].
The use of promoters that have a certain tissue-spe-
cific activity allows one to solve a number of problems 
associated with the nonspecific toxicity of the delivery 
vector. Thus, adenoviral vectors have considerable re-
strictions caused by the low efficacy of the transduc-
tion of melanoma cells, due to the low concentration or 
absence of the coxsackievirus and adenovirus recep-
tors (CAR) that mediate cell transduction on melanoma 
cells [84]. The introduction of high doses of adenovi-
ruses had a negative effect on the organism in general.   
Constructs of AdRGD adenoviruses that possess tro-
pism towards αV-integrins and transduce melanoma 
cells more efficiently as compared with the standard 
adenoviruses have been created [85]. Nevertheless, the 
systemic introduction of such adenoviral constructs re-
sulted in nonspecific transduction and death of normal 
cells. The problem was solved by using specific promot-
ers. AdRGD adenoviruses containing the HSVtk suicide 
gene under the transcriptional control of the tumor-
specific promoter TERT or melanoma-specific promot-
er Tyrex2, instead of the standard nonspecific CMV 
promoter, turned out to be promising for melanoma 
therapy [86]. A decrease in the size of mice tumors was 
observed upon intratumoral introduction of AdRGD-
TERT-HSVtk or AdRGD-Tyrex2-HSVtk, after subse-
quent administration of ganciclovir . The same effect is 
achieved by the introduction of low doses of nonspecific 
AdRGD-СМV-HSVtk; however, in this case increasing 
the dose of the vector resulted in weight loss and hepa-
totoxicity in the mice [86]. On the other hand, even an 
intravenous introduction of high doses of the AdRGD-
TERT-HSVtk or AdRGD-Tyrex2-HSVtk vector does 
not cause toxic damage to the liver. Thus, the suppres-
sion of the nonspecific cytotoxicity of adenoviruses in 
normal nontumor cells is achieved via the use of spe-
cific promoters [86].
The size of the promoter plays a significant role in 
the design of efficient gene therapy agents, since many 
vectors are characterized by their limited capacity. 
Thus, it has been demonstrated that in retroviral vec-
tors containing long promoter modules, the viral titer 
typically decreases when the size of the promoter in-
troduced is increased [87]. However, a large number of 
short promoters are either very weak or lose their tis-
sue specificity; therefore, the possibility of constructing 
short and specific promoters that would possess suf-
ficient transcriptional potential is a considerable task. 
Construction of synthetic and/or double (chimeric) 
promoters may become a method that could allow to 
overcome these limitations.
CONSTRUCTION AND OPTIMIZATION OF 
SYNTHETIC AND DOUBLE PROMOTERS 
POSSESSING TISSUE-SPECIFIC ACTIVITY
The controlling elements of the known promoters that 
have been characterized are used to construct de novo 
specific promoter modules. For instance, artificial pro-
moters based on the elements of the promoters of the 
human tyrosinase and α-fetoprotein (AFP1) genes pos-
sessing strong and specific expression in melanoma cell 
lines were constructed [88]. As previously mentioned, 
the tyrosinase promoter contains the M-box, the con-
servative element that is common to melanocyte-spe-
cific promoters [89]. This element was used in combina-
tion with the elements from the 5’-region of the AFP1 
promoter – the GRE element, which is specific for the 
cell cycle and the AP1-binding element. Several ef-
ficient melanocyte-specific promoters were obtained REVIEWS
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upon different combinations of one or several copies of 
fragments of the tyrosinase and α-fetoprotein promot-
ers – the M-box, AP1 and GRE elements. These pro-
moters were selectively active in the B16 melanoma 
line, but not in the HeLa cell line [88]. The length of the 
artificial constructs was not more than 300 bp; the pro-
moter consisting of three GRE, three AP1 elements, 
and two M-boxes was the most efficient one. It was as-
certained that if the number of regulatory elements of 
the promoter in the chimeric construct is higher than 
eight units, a loss in promoter specificity is observed 
[88]. It seems that the activity of synthetic promoters 
is dependent both upon the number of regulatory el-
ements and upon the vector. The optimal number of 
regulatory elements has to be selected in each case. For 
example, it was shown in the above-mentioned study 
by Rothfels et al. [22] that it is sufficient to bind four 
copies of the enhancers of the mouse tyrosinase gene in 
order to increase the activity of both the MIA and TYR 
promoters. 
Another approach to constructing specific promot-
ers consists in the construction of chimeric or double 
promoters.
As previously mentioned, most tumor-specific pro-
moters show lower activity in comparison with con-
stitutive strong promoters, such as the promoters of 
the SV40 and CMV viruses. One of the approaches that 
help to resolve the problems related to the efficacy of 
tumor-specific promoters is the use of hybrid double 
promoters: (i) one of them being tumor-specific, while 
the second is a strong nonspecific promoter; (ii) each 
promoter being tumor-specific. The double promoters 
described exhibit a higher activity in tumors of a cer-
tain type in comparison with natural promoters.
The chimeric promoter CMV-hTERT is an example 
of the first construct [90]. The chimeric construct was 
obtained on the basis of the promoter of the human tel-
omerase reverse transcriptase (hTERT) gene and the 
minimal CMV promoter, which is characterized by a 
higher activity in comparison with the nonmodified 
hTERT promoter, while it retains tumor specificity.
Double tumor-specific promoters have also been de-
scribed [91, 92]. In order to increase the efficacy of ex-
pression of therapeutic genes in small lung cancer cell 
(SCLC), a chimeric double promoter based on promot-
ers of the hASH1 and EZH2 genes with a high level of 
expression in SCLC cells was obtained. The activity of 
the double chimeric promoter was higher than the ac-
tivities of the corresponding single promoters by up to 
1–8 fold, depending on the cell line of SCLC [92].
In another study, a high level of expression of apop-
tosis activator tBid in breast cancer cells was achieved 
via the use of a hybrid promoter consisting of promot-
ers of the human survinin gene and the gene encoding 
glycoprotein mucin; its expression increased in breast 
cancer cells [91]. Thus, the use of double promoters 
permits one to provide a high level of expression of the 
therapeutic gene in tumor cells, retaining specificity 
towards cancer. The use of double tumor-specific pro-
moters facilitates the construction of more universal 
gene therapeutic constructs: i.e., constructs that pro-
vide the expression of the therapeutic gene in many 
types of cancer cells. For instance, a vector bearing two 
DT-A gene fragments controlled by the promoters of 
the IGF2-P4 and H19 genes was constructed [93]. The 
introduction of this vector to  cells of several lines of 
urinary bladder cancer ensured  gene expression in all 
lines, whereas the DT-A gene controlled by one of the 
promoters, IGF2-P4 or H19, exhibited activity not in all 
the lines of tumor cells that were used.
No systems of double promoters containing melano-
ma-specific promoters have been described yet. How-
ever, the construction of systems based on melanoma-
specific promoters, such as promoters of the MIA and 
TYR genes, could provide a universal, highly efficient, 
and specific expression of the therapeutic gene in mela-
noma cells.
CONCLUSION
Melanoma treatment is associated with a number of 
difficulties, including the high resistance of melano-
ma cells and early metastazing, which determine the 
unfavourable prognosis. The necessity to affect the 
metastatic loci disseminated over the entire organism 
requires the systemic administration of antimelanoma 
agents, which involves a certain risk that other cells of 
the organism can be affected. Gene therapy, which has 
known rapid development, offers new methods that 
allow to increase the specificity of the effect on mela-
noma cells whilst simultaneously decreasing the prob-
ability of damaging healthy cells. The use of melano-
ma-specific promoters makes it possible to specifically 
affect melanoma cells. These methods have recently 
gone into the stage of development and are perma-
nently being improved to find the most efficient solu-
tions, starting with the selection of optimal regulatory 
elements, the designing of constructs based on these 
elements, and ending with the search for new vectors, 
with both natural viruses or artificially constructed 
systems for packing the genetic material being used 
as such vectors [94, 95]. One can hope that a simple and 
efficient system for the elimination of melanomas and 
its metastases will be designed. 
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